结直肠癌预后标志物:倍体与间质评估
该研究利用2624例早期结直肠癌患者的FFPE组织,通过自动化数字成像系统评估DNA倍体和肿瘤-间质比例,并以5年癌症特异性生存(CSS)为终点分析预后价值。在II期患者中,倍体与间质比例联合可将其分为三个临床风险组,5年CSS分别为90%、83%和73%,风险比具有统计学显著性。
要点
- 倍体与间质比例联合可对II期结直肠癌进行风险分层
- 三组5年CSS分别为90%、83%和73%
- 该标志物可能辅助II期患者辅助治疗决策
核心结论
- 联合倍体与肿瘤-间质比例的标志物可将II期结直肠癌患者分为低、中、高风险组,区分肿瘤复发风险,可能支持辅助治疗选择。
研究设计与样本
- 研究纳入2624例早期结直肠癌患者,样本来自QUASAR 2试验(1092例)及两个观察性系列(Gloucester n=954;Oslo University Hospital n=578)。
- 使用自动化数字成像系统评估DNA倍体和间质-肿瘤比例,并从FFPE组织提取DNA分析微卫星不稳定性。
- 以5年癌症特异性生存(CSS)为临床终点,在多变量模型中分析预后影响。
主要发现
- 在II期患者中,经年龄、辅助治疗和病理T分期调整的多变量模型显示,倍体和间质-肿瘤比例具有显著预后价值。
- 倍体与间质-肿瘤比例联合将II期患者分为三组,5年CSS分别为90%、83%和73%。
- 风险比:HR=1.77(95%CI 1.13-2.77)和HR=2.95(95%CI 1.73-5.03),P<0.001。
关键数值与推荐
- II期结直肠癌患者根据倍体与间质-肿瘤比例联合评估分为三组,5年CSS分别为90%、83%和73%。
- 组间比较HR分别为1.77(95%CI 1.13-2.77)和2.95(95%CI 1.73-5.03),P<0.001。
临床怎么用
- 对于II期结直肠癌患者,可基于FFPE组织评估倍体和间质-肿瘤比例,辅助识别低、中、高风险亚群。
- 该标志物可能帮助临床医生针对不同复发风险患者个体化选择辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report here the prognostic value of ploidy and digital tumour-stromal morphometric analyses using material from 2624 patients with early stage colorectal cancer (CRC). PATIENTS AND METHODS: DNA content (ploidy) and stroma-tumour fraction were estimated using automated digital imaging systems and DNA was extracted from sections of formalin-fixed paraffin-embedded (FFPE) tissue for analysis of microsatellite instability. Samples were available from 1092 patients recruited to the QUASAR 2 trial and two large observational series (Gloucester, n = 954; Oslo University Hospital, n = 578). Resultant biomarkers were analysed for prognostic impact using 5-year cancer-specific survival (CSS) as the clinical end point. RESULTS: Ploidy and stroma-tumour fraction were significantly prognostic in a multivariate model adjusted for age, adjuvant treatment, and pathological T-stage in stage II patients, and the combination of ploidy and stroma-tumour fraction was found to stratify these patients into three clinically useful groups; 5-year CSS 90% versus 83% versus 73% [hazard ratio (HR) = 1.77 (95% confidence interval (95% CI): 1.13-2.77) and HR = 2.95 (95% CI: 1.73-5.03), P < 0.001]. CONCLUSION: A novel biomarker, combining estimates of ploidy and stroma-tumour fraction, sampled from FFPE tissue, identifies stage II CRC patients with low, intermediate or high risk of CRC disease specific death, and can reliably stratify clinically relevant patient sub-populations with differential risks of tumour recurrence and may support choice of adjuvant therapy for these individuals.
引用
- Danielsen HE, Hveem TS, Domingo E, et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann Oncol. 2018. PMID: 29293881. doi:10.1093/annonc/mdx794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。